RecruitingPhase 2NCT07283705
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
Sponsor
M.D. Anderson Cancer Center
Enrollment
60 participants
Start Date
May 18, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
To find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Cohorts 2 and 3) can help to control pancreatic cancer.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called BMS-986504, a drug called Gemcitabine, and others for people with bms-986504, mtap-deleted pancreatic cancer, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBMS-986504
Given by po
DRUGGemcitabine
Given by IV
DRUGNab-paclitaxel
Given by IV
DRUGmFOLFIRINOX
Given by iv
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07283705